Skip to main content
. Author manuscript; available in PMC: 2023 Apr 11.
Published in final edited form as: Cancer Immunol Res. 2021 Aug 3;9(10):1214–1228. doi: 10.1158/2326-6066.CIR-21-0265

Figure 5.

Figure 5.

Expansion of intratumoral stem-like/progenitor exhausted CD8+ T cells by minP1/anti–PD-L1 treatment is associated with an increased number of mregDCs in tumors. A, Schema on the preparation of tumor immune cells from Colon26 or LLC tumor–bearing mice. FCM, flow cytometry. B, The number of CD8+ T cells in the tumors of Colon26 or LLC tumor–bearing mice on day 12 after tumor inoculation. CD45IVS, intravenous CD45 staining. C, Scatter plots of mregDCs and CD8+ T-cell numbers in tumors. The symbol color reflects different treatment groups. D, Flow cytometry gating of intratumoral Tstem/Tpex (Ly108+TIM-3−CD8+) and Tex (Ly108−TIM-3+CD8+) cells. The tSNE defines the Tstem/Tpex and Tex populations among CD8+ T cells and displays the fluorescence intensity of CD44, PD-1, Ly108, and TIM-3 in this population. GMFI, geometric MFI. E, Expression of the intracellular cytokines IFNg, IL2, and TNFα. Cell populations 1 to 3 correspond to populations indicated in D. F, Heatmap of the top 15 DEGs among the Tstem/Tpex, Ttran, and Tex cell subsets. G and H, The compartments, frequencies, and numbers of Tstem/Tpex (Ly108+TIM-3−CD8+), Ttran (Ly108+TIM-3+CD8+), and Tex (Ly108−TIM-3+CD8+) cells in the tumors of LLC or Colon26 tumor–bearing mice on day 12 after tumor inoculation. I, Scatter plots of mregDCs and Tstem/Tpex cell numbers or mregDCs and Tex cell numbers in tumors. The symbol color reflects different treatment groups. Each result is representative of three independent experiments with at least four mice/group. Data are presented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 using Dunnett post hoc test (compared with control); #, P < 0.05; ##, P < 0.01; ###, P < 0.001 using Student t test (comparing between minP1/anti–PD-L1–treated and anti–PD-L1–treated groups).